The efficacy and acceptability of oral oxamniquine were assessed in Sudanese patients infected with Schistosoma mansoni. Cure rates, determined by the absence of viable eggs in the stools six months after treatment, were 94-9% in patients treated with a total of 60 mg/kg, 788% in patients treated with 40 mg/kg, and 689% in patients treated with 30 mg/kg. All treatment regimens considerably reduced the egg count in those patients not cured.
Introduction
Schistosomiasis is a major and increasing public health problem in the Sudan. The prevalence of infection has increased sharply in the past 25 years in the irrigated Gezira area of the Sudan; it is now 80"O in children' compared with 14°, in 1952.' The recent expansion in agriculture will probably cause the spread of the disease to new provinces and resettlement areas. Nubians who were resettled in eastern Sudan after the building of the Aswan High Dam rapidly acquired Schistosoma mansoni infection, a disease unknown in their original home, and the prevalence in some regions of the resettlement area rose to 25,", among children within five years. Irrigation by pump schemes in different parts of the country has also contributed to the spread of the disease. 4 Antimony treatment dominated schistosomiasis chemotherapy for over 40 years. Treatment was long term and produced many side effects. Niridazole and hycanthone emerged later, the former having the advantage of being the first successful oral treatment and the latter of giving a high cure rate with a single injection. Both, however, produce side effects, which are sometimes severe. Metrifonate emerged as another successful oral treatment with minimal side effects but was successful only in treating S haematobiuim infestations and in the unusual presentation of S mansoni in the urine. 5 Preliminary work in animals has shown that oxamniquine (Vansil), a tetrahydroquinoline derivative, produces high cure rates in S mansonii infection with minimal toxicity after a short treatment period.6 But the dose response in humans varies in different regions, and local investigations are therefore needed.8
The aim of this study was to find the optimal regimen for use in the Sudan.
Patients and methods
The clinical trial was conducted on patients reporting to the Hospital (P < 0 05), and total white cell count (P = 0-01). The rise in the white cell count was due to the eosinophilia, as there was no significant increase in the other cell counts. Table III The incidence of side effects in both groups is shown in table I, there being more side effects in those receiving the higher doses.
Discussion
The parasitological findings of this study, based on final numbers reporting, showed that oxamniquine produced a 950,, cure rate six months after treatment when given in doses of 15 mg/kg twice daily for two days. When the total dose was reduced to 40 mg/kg and 30 mg/kg the cure rates six months after treatment dropped significantly to 79"o and 690,, respectively.
These findings do not agree with results in South America, where Da Silva et al1 reported a cure rate of 100"/ in patients who received 15 mg/kg body weight. Omgom et all' in Uganda reported cure rates of 83-3-91 6°0 after a total dose of 40 mg/kg body weight. The morbidity of the disease in the Sudan may, however, be different from that in other regions'; indeed the disease varies in severity within the Sudan itself. Whether these differences are due to strain difference, acquired resistance to the infection, or the nutritional status of the host is not known, and is under investigation. The results of oxamniquine treatment were, however, found to be much better in animals infected with a Puerto Rican strain than in those infected with an East African strain of S nzansoni.'2 Another factor is the possibility of previous antischistosomal treatment, in which repeated and often incomplete courses of drugs are given and which may have caused cross resistance. Other factors may also affect the absorption of oxamniquine and possibly prevent curative blood concentrations from being reached. Blood concentrations of oxamniquine were investigated in patients on the low-dose and high-dose regimens in this study, and the results will be reported elsewhere.
The side effects of oxamniquine were minimal and transient. Most other workers have reported similar minimal side effects but their doses were lower.13 14 The most common side effect was dizziness; 11 of those taking the 60 mg,/kg dose complained of this symptom compared with only one of those receiving a total dose of 30 mg/kg, which suggests that the symptom may be dose dependent. Abdominal pain and diarrhoea also occurred but were mild. Although these symptoms are common in patients with S mansonii infection, they were probably caused, at least in part, by the drug since they occurred immediately after treatment.
Most (53) of the patients on a total dose of 60 mg/kg passed reddish urine on the second day of treatment. No other urinary abnormality was found, and a metabolite of the drug might have been responsible. I am unaware of any similar findings by other workers, but patients should be warned so that they do not become alarmed.
Eosinophilia has been reported after antichistosomal treatment with hycanthone.') 16 And the eosinophil count increased significantly in the patients in this study. This may represent an immunological response to the dying worms and release of antigens, as the peak increase had occurred by day 12. The only abnormality in liver function values was a transient rise in SGPT on the fifth and 12th days after treatment. Axton and Garnett'-noticed no significant changes in the SGPT in their patients after oxamniquine treatment, while Prata et al'3 reported increases in both SGOT and SGPT. Our patients showed no significant change in SGOT, but oxamniquine was given orally, and the increase in SGOT in the trial of Prata et al might be explained by the use of intramuscular injections and resulting myositis. The rise in the SGPT in our patients may suggest either a transient hepatic toxicity caused by the drug, or a shift of worms to the liver. The role played by each factor is difficult to determine.
The fact that oxamniquine was also effective in reducing the egg count in patients who were not cured may prove useful in control programmes. The percentage reduction in the number of eggs was over 900, on the total dose of 60 mg/kg, and there was a smaller but still significant reduction in the number of eggs on the 40 mg/kg and 30 mg/kg doses. These findings suggest that control programmes in developing countries can use lower doses, and so reduce costs, to effectively reduce transmission of S mansoni infection, despite the lower cure rate.
Introduction
Autoantibodies to pancreatic islet cells were first described in patients with diabetes mellitus who also had polyendocrine autoimmune diseases.' 2 Islet-cell antibodies were subsequently found in 60-850o of newly diagnosed patients with juvenile diabetes.3 In these patients the antibodies are strongly associated with diabetes of short duration, and two to five years after diagnosis their prevalence has fallen to less than 2000. [4] [5] [6] Whether an association exists between islet-cell and thyrogastric antibodies is unclear,4 and there are few data on thyrogastric
